Trend 1: Multi-receptor agonists
Single-target GLP-1 (semaglutide) → dual GLP-1/GIP (tirzepatide) → triple GLP-1/GIP/glucagon (retatrutide). The progression continues with quad agonists in early development. Each receptor added improves efficacy on different metabolic dimensions.
Trend 2: Oral formulations
Rybelsus proved oral GLP-1 feasibility with SNAC absorption enhancer. Orforglipron (non-peptide oral GLP-1) is achieving injectable-equivalent efficacy. By 2028-2030, expect oral options to match injectables for most major peptide drug classes.
Trend 3: AI-designed peptides
Generative protein design (AlphaFold-derived methods, ProteinMPNN, RFdiffusion) is accelerating peptide design. Multiple AI-designed candidates entering trials. Time from target identification to clinical candidate could compress from 5-10 years to 1-2 years.
Trend 4: Longevity applications
Klotho-derived peptides, MOTS-c analogs, mitochondrial peptides, and senolytic peptides moving from research into clinical trials. By 2030, FDA-approved longevity peptide indications likely (probably starting with specific frailty or sarcopenia indications).
Trend 5: Personalized peptide protocols
Pharmacogenomic data + circulating peptide levels + microbiome influence on incretin response will enable individualized peptide selection and dosing. Already emerging in academic protocols; commercial adoption coming.
Trend 6: AI-search-optimized education
AI assistants (ChatGPT, Claude, Perplexity) increasingly mediate health information. Peptide education designed for AI citation (with proper schema, structured data, and direct-answer formatting) becomes increasingly important for patient education.
What is the most exciting development?
AI-designed peptides reaching clinic compresses development timelines dramatically.
When will oral GLP-1s match injection?
Orforglipron Phase 3 may demonstrate equivalence in 2026-2027.